21,432 Shares in Immuneering Co. (NASDAQ:IMRX) Acquired by Marshall Wace LLP

Marshall Wace LLP purchased a new stake in Immuneering Co. (NASDAQ:IMRX) in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 21,432 shares of the company’s stock, valued at approximately $47,000. Marshall Wace LLP owned 0.07% of Immuneering as of its most recent SEC filing.

Several other institutional investors have also modified their holdings of IMRX. HighTower Advisors LLC boosted its holdings in Immuneering by 33.7% in the fourth quarter. HighTower Advisors LLC now owns 71,360 shares of the company’s stock valued at $157,000 after purchasing an additional 18,000 shares during the period. XTX Topco Ltd grew its position in shares of Immuneering by 177.2% during the fourth quarter. XTX Topco Ltd now owns 32,650 shares of the company’s stock worth $72,000 after buying an additional 20,871 shares in the last quarter. Finally, Rockefeller Capital Management L.P. purchased a new stake in shares of Immuneering during the fourth quarter worth approximately $390,000. Institutional investors and hedge funds own 67.65% of the company’s stock.

Immuneering Stock Performance

IMRX opened at $1.21 on Wednesday. Immuneering Co. has a one year low of $1.00 and a one year high of $3.83. The company has a market cap of $43.36 million, a P/E ratio of -0.61 and a beta of -0.22. The business’s 50-day simple moving average is $1.45 and its 200-day simple moving average is $1.80.

Immuneering (NASDAQ:IMRX) last announced its quarterly earnings results on Monday, May 5th. The company reported ($0.42) EPS for the quarter, missing the consensus estimate of ($0.41) by ($0.01). As a group, analysts predict that Immuneering Co. will post -1.86 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages recently issued reports on IMRX. Needham & Company LLC reiterated a “buy” rating and issued a $12.00 price target on shares of Immuneering in a research note on Thursday, April 10th. Chardan Capital reaffirmed a “buy” rating and set a $13.00 price objective on shares of Immuneering in a research report on Tuesday.

Immuneering Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.